Ojemda savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Ojemda

We didn’t find one.

Ask your pharmacy for Ojemda’s cash price, and one or two other pharmacies too.
Ojemda’s savings card works only with insurance from a job or one you bought.

Compare every option

Brand nameOjemda

Authorized generictovorafenib

Regular generictovorafenib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Ojemda?

The original

–

Brand nameThe maker’s card

OJEMDA Copay Program (EveryDay Support From Day One)

Savings card from Day One Biopharmaceuticals

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

Or call 1-855-329-1246. See the offer on ojemda.com

In the maker’s words

“the OJEMDA Copay Program, which can lower out-of-pocket costs to as little as $0 per month…”

From the maker’s offer on ojemda.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Ojemda itself, from the same company, sold without the brand name, and usually for less. For now Ojemda is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Childhood low-grade glioma (brain tumor) with a BRAF change

What the FDA label says

OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Ojemda (Day One Biopharmaceuticals, Inc.), September 2, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/ojemda/